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A B S T R A C T
Molecular docking studies using appropriate 5-HT1A, 5-HT2A and D2 receptors models were used to design
sixteen new 5-hydroxycoumarin derivatives with piperazine moiety (3–18). The microwave radiation have been
used to synthesize them and their structures have been confirmed using mass spectrometry, 1H and 13C NMR. All
newly prepared derivatives were evaluated for their 5-HT1A, 5-HT2A and D2 receptor affinity. Seven of the
synthesized derivatives showed very high affinities to 5-HT1A receptor (3–4.0 nM, 6–4.0 nM, 7–1.0 nM,
9–6.0 nM, 15–4.3 nM, 16–1.0 nM, 18–3.0 nM) and one of them showed high affinities to 5-HT2A receptor
(16–8.0 nM). In the case of the D2 receptor none of the tested derivatives showed high affinity. Compounds 7 and
16 were identified as potent antagonists of the 5-HT1A receptor as shown by the [35S]GTPcS binding assay but
they didn’t show any antidepressant effect at the single dose tested (10 mg/kg) in the tail suspension tests.
1. Introduction
Among many families of G protein-coupled receptors (GPCRs) those
implicated in proper brain function and mental disorders have always
garnered a lot of attention. 5-HT receptors modulate the release of
many neurotransmitters and are the target of a variety of drugs, in-
cluding antidepressants, antipsychotics, hallucinogens anorectics and
antimigraine agents [1–4]. Dopamine receptors are also an important
class of GPCR in the vertebrate central nervous system, implicated in
many neurological processes and being the target of neurologic drugs
[5–7]. D2 receptor antagonism represents a key feature of antipsychotic
activity that allows mitigation of the positive symptoms of schizo-
phrenia by reducing excessive dopamine signaling in the mesolimbic
pathway. Additionally, affinity at the 5-HT1A, 5-HT2A and 5-HT2C re-
ceptors reduce side effects of dopamine depletion in the mesocortical
and nigrostriatal dopamine pathways including negative symptoms of
schizophrenia, motor dysfunctions and cognitive impairments [8].
Moreover, previous investigations pointed to the possibility that
blockage of the 5-HT1A autoreceptors accelerates the antidepressant
effects of SSRI’s by augmenting extracellular serotonin release in the
frontal cortex and hippocampus [9–10]. A promising new 5-HT1A au-
toreceptor antagonist, MIN-117 was entered into a phase 2 clinical trial
for the treatment of major depressive disorder (MDD) and showed a
more favorable tolerability profile than a classical SSRI, but was less
efficacious [11–12].
N-arylpiperazine derivatives are a large class of compounds active
against one or several serotonin 5-HT and dopamine receptors [13–14].
The first literature reports on the action of N-phenylpiperazinyl deri-
vatives of coumarins appeared in 1998 [15]. Further research carried
out over the last 20 years allowed to determine which elements of the
structure of arylpiperazine derivatives of 7-hydroxycoumarin are re-
sponsible for the high affinity to serotonin 5-HT1A, 5-HT2A and dopa-
mine D2 and D3 receptors [15–19]. In 2017, based on the results of
these works, we designed a series of arylpiperazine derivatives of 7-
hydroxycoumarin [20–21], which showed subnanomolar affinities to 5-
HT1A receptor and low nanomolar affinities to 5-HT2A receptor. In all
cases high affinity was obtained for compounds with a methyl group in
position C-4 at the coumarin ring, and an acetyl group in position C-8.
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We also found that the position of substituents on the phenyl ring on the
piperazine was very important for biological activity. The chemical
nature of these substituents was found to be less important, since both
electron-withdrawing (chloro, bromo) and electron-donating (methoxy)
moieties in the ortho and/or meta positions of the phenyl ring of pi-
perazine gave the highest affinities. Additionally, we discovered that
the alkyl chain length between coumarin and piperazine moiety, varied
between three and four carbon linkers, did not significantly affect li-
gand affinities.
Similar results were also obtained for a series of arylpiperazine
derivatives of 5-hydroxycoumarin, which we synthesized in the same
year [22]. We showed that the highest, subnanomolar affinities for 5-
HT1A receptor were associated with the presence of the acetyl group in
the C-6 position at the coumarin ring and the substituents in the 2 or 3
position in the phenyl ring of piperazine. High affinities were achieved
by compounds with both the three-carbon and four-carbon alkyl chains
between the coumarin and piperazine moieties. Nevertheless, the best
results for 7-hydroxycoumarin derivatives were obtained for the four-
carbon linker while for 5-hydroxycoumarin derivatives for the three-
carbon linker.
Guided by these findings our group was encouraged to design a new
series of arylpiperazinyl derivatives of 6-acetyl-5-hydroxy-4,7-di-
methylcoumarin. In this study we used arylpiperazine derivatives from
our previous study as a starting point for optimization of ligands against
5-HT and D2 receptors. We have performed docking studies of 16 new
coumarin derivatives to 5-HT1A, 5-HT2A and D2 receptors followed by
their synthesis and receptor binding assays. Additionally, functional
assays and in vivo tests were performed for two selected derivatives (7
and 16) that showed high affinity to 5HT1A receptor.
2. Results and discussion
2.1. Molecular docking studies
The results of the molecular docking calculations for the new series
of hydroxycoumarin derivatives are presented in Table 1. As in our
previous reports most of these derivatives show relatively high affinities
to 5HT1A receptor, but also, unlike in our former studies, similarly high
affinities to 5HT2A receptor [22].
We decided to perform a more detailed, atomic-scale analysis of the
two compounds with the best predicted affinity to 5HT1A receptor,
namely 3 and 15; these have been later confirmed to also have similarly
high experimental affinities (1.0/4 nM for 3 and 2.3/4.3 nM for 15). In
both cases, and in all docked 5HT1A ligands, the ligand is anchored in
the binding site via a well-known salt-bridge between D116 and the
basic nitrogen atom of the piperazine, while finding additional favor-
able interactions with F361, Y390 and either I385 or N392 (Fig. 1).
Interestingly, the docked poses of ligands with predicted binding up to
the 12 nM range are all very similar with the hydroxycoumarin deri-
vatives interacting with the same residues, though in all cases they
show two major arrangements; on with the coumarin part closer to
transmembrane helices 3 and (as in the case of 3) and with this part
closer to helices 5–6 (as in the case of 15). Overall, given the expected
accuracy of the method it’s difficult to choose with high confidence one
or two derivatives with the highest expected affinity.
As stated before the computational results for the 5HT2A receptor
docking are quite surprising, since in or previous studies most the
coumarin derivatives active against 5HT2A receptor had lower affinities
to 5HT2A receptor, but the agreement between the computational and
experimental data was reasonably good [21,22]. Current results do not
follow the trend, as the 5HT2AR computational affinity values are
somewhat high, on the level of the 5HT1AR values, and clearly not in
agreement with the experimental data presented in the experimental
part of this study. For now we don’t have an explanation for these re-
sults apart from the imperfectness of our homology 5HT2AR model
which is based on the β1 adrenergic receptor.
Additionally, we also performed computational docking studies do
the D2 receptor. Here, the results were similar to the 5 HT2AR case, as
most of the studies systems showed high computational affinities to
D2R, but very low experimental affinities. The high estimated compu-
tational affinities are mostly due to a strong salt bridge between D114
and the basic nitrogen atom of the piperazine, similarly to the 5HT1A/
Table 1
Computational Ki values to serotonergic 5-HT1A and 5-HT2A and dopaminergic
D2 receptors and compounds 3–18.
Compound 5-HT1AR 5-HT2AR D2R
Ki [nM]
3 1.02 35.31 5.36
4 4.55 17.89 4.51
5 3.01 6.28 13.44
6 48.04 18.06 15.97
7 11.77 2.90 7.58
8 11.74 8.81 6.66
9 8.55 58.25 4.88
10 4.92 3.16 5.29
11 4.92 3.68 8.62
12 3.61 7.87 7.10
13 27.39 4.77 6.45
14 25.10 4.26 7.82
15 2.30 12.43 2.90
16 11.92 19.21 4.21
17 700.08 11.00 17.63
18 22.04 30.85 12.16
Fig. 1. Computational binding poses of (a) 3 and (b) 15 to 5HT1A receptor.
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2AR cases. This is also the same interaction that anchors the ligand in
the binding pocket of the crystal structure of risperidone-D2R complex
via the salt bridge to the basic nitrogen of the piperidine moiety. Given
the presence of this interaction, similar shape of risperidone and hy-
droxycoumarin series as well as similar poses for any studied hydro-
xycoumarins, which align well with the crystal structure of risperidone
(Fig. 2) the final, experimental, low affinities are quite puzzling, even
taking into the account the expected accuracy of the docking algorithm
of around 1–2 kcal/mol.
2.2. Chemistry
A series of sixteen new arylpiperazinyl derivatives of 6-acetyl-5-
hydroxy-4,7-dimethylcoumarin (3–18) were synthesized in two steps.
First, intermediate bromoalkyl compounds (1–2) were prepared ac-
cording to known procedures [20]. 6-Acetyl-5-(3-bromopropoxy)-4,7-
dimethylcoumarin (1) and 6-acetyl-5-(4-bromobutoxy)-4,7-di-
methylcoumarin (2) were prepared using microwave heating, from 6-
acetyl-5-hydroxy-4,7-dimethylcoumarin and 1,3-dibromopropane or
1,4-dibromobutane as a substrates, in the presence of K2CO3 and KI in
acetonitrile. In the next step, the final two series of new compounds
(3–10, 11–18) were obtained in the reaction of the suitable alkylating
agent (1 or 2) and the corresponding N-substituted piperazine. Acet-
onitrile was used as a solvent and the reaction proceeded in the pre-
sence of potassium iodide and potassium carbonate, using a microwave
reactor. The synthetic protocol is outlined in Scheme 1.
A column chromatography with appropriate solvents was used to
purify new compounds. The structure of 1–18 was confirmed by ap-
pearance of two additional triplets in the range of 2.5–4.0 ppm derived
from alkyl groups on the propane/butane (for 1′, 3′ or 1′, 4′ protons,
respectively) and two multiplets in the range of 1.50–2.00 ppm from
the remaining alkyl propane/butane groups (2′ or 2′, 3′, respectively) in
1H NMR spectra. The presence of additional peaks in the aromatic range
(compared to compounds 1, 2) from the phenyl ring and signals in the
range 3.50–2.50 ppm derived from the CH2 groups in the piperazine
ring, also confirmed the structures of 1–18. In the spectra of derivatives
4–5, 9–10, 12–13 and 17–18, we also observed additional signals from
appropriate substituents from the piperazine phenyl ring.
2.3. In vitro affinity tests
In continuation with our efforts toward the identification of novel
derivatives with serotonin 5-HT and dopamine receptors affinities, we
evaluated the activity of the target systems to 5-HT1A, 5-HT2A and D2
receptors using the radioligand binding assay. To determine whether
the substituents in the phenyl ring have an effect on the activity,
compounds with various groups attached to the phenyl ring were
compared. The data (Table 2) showed that some of newly synthesized
compounds possessed very high, nanomolar-range affinities to 5-HT1A
receptors. Among all investigated derivatives we found that those with
electron-withdrawing (3-bromo, 3-fluoro) as well as electron-donating
(2-methoxy) groups, (7, 16 and 18, respectively) were able to bind
strongly to 5-HT1A receptor and showed affinities at or below the level
of DPAT (Ki = 1.0 ± 0.05).. Furthermore, derivatives containing 2-
chloro, 2-bromo and 2-trifluoromethyl substituents (3, 6, 9), also
showed high affinity to 5-HT1A receptor with the Ki values of
4.0 ± 0.4, 4.0 ± 0.5 and 6.0 ± 0.5, respectively. Clearly, the sub-
stitution at the phenyl ring is important for their activities. We also
observed that for derivatives with a three-carbon linker replacing the
chlorine in position C2 of the phenyl ring with bromine or a tri-
fluoromethyl group resulted in no change or small decrease of the ac-
tivity of the derivatives (compounds 3, 6 and 9). We also observed an
over 106-fold activity loss when bromine moiety in C3 position of the
phenyl ring was replaced with fluorine and 45-fold activity loss when it
was replaced with two methyl groups in C3 and C5 positions (com-
pounds 7, 8 and 4). For derivatives with four-carbon linker, replacing
the methoxy group in C2 position with bromine, chlorine or tri-
fluoromethyl group caused a decrease in activity, but bromine was the
most preferred substituent and the trifluoromethyl group gave the de-
rivative with the lowest affinity (compounds 18, 14, 11 and 17).
However, in a set of derivatives with substituents at the C3 position and
the four-carbon linker, the best affinity to the 5-HT1A receptor was
obtained for the fluorine derivative 16. Replacement of fluorine with
bromine or methyl groups at the C3 and C5 positions caused a decrease
in activity (compounds 16, 15 and 12).
Comparisons of compounds that differ only in the length of the alkyl
chain between the coumarin and piperazinyl moiety leads to no simple
structure-activity relationships. If we take into account e.g. 7 (3-carbon
linker) and 15 (4-carbon linker) their affinity to 5-HT1A receptor is si-
milar but higher for 7 (Ki = 1.0 ± 0.05 for 7 or Ki = 4.3 ± 0.4 for
15). On the other hand, for compounds 8 (3-carbon linker) and 16 (4-
carbon linker) we found much better affinities for the latter compound
(Ki = 106.0 ± 10.5 for 8 and Ki = 1.0 ± 0.1 for 16). In the 10 (3-
carbon linker) and 18 (4-carbon linker) pair, the derivative with the
four-carbon linker had higher affinity, while in 3/11 and 6/14 pairs the
derivatives with the three-carbon linker showed higher affinities (no
result obtained for 10 and Ki = 3.0 ± 0.3 for 18; Ki = 4.0 ± 0.4 for 3
and Ki = 38.0 ± 5.5 for 11; Ki = 4.0 ± 0.5 for 6 and
Ki = 17.0 ± 2.0 for 14).
The affinity of the 3–18 series of compounds to 5-HT2A receptor was
also examined. Our studies have shown that new derivatives have
moderate activity towards this receptor and none was active at the level
of mianserin, which was used as a reference compound
(Ki = 1.7 ± 0.1 for mianserin). The best results were obtained for 6-
acetyl-5-(4-(4-(3-fluorophenyl)piperazin-1-yl)butoxy)-4,7-dimethyl-
2H-chromen-2-one (16) (Ki = 8.0 ± 1.1). Its three-carbon linker
analogue (8) had the 5-HT2A receptor affinity drastically decreased
(Ki > 1000). It is worth noting that compound 16, with (3-fluor-
ophenyl)piperazinyl moiety and four-carbon linker showed the highest
affinity for both the 5-HT1A and 5-HT2A receptors. The remaining
compounds showed affinities to 5-HT2A receptor which were 1–3 orders
of magnitude lower. High affinity for the 5-HT2A receptors was also
demonstrated by derivatives of both the three- and four-carbon linker
with bromine at the C2 or C3 position of the phenyl ring on piperazine.
Substitution of bromine with chlorine caused a decrease in activity, as
did its conversion to a trifluoromethyl or methoxy group.
A similar situation was found in the case of the D2 receptor affi-
nities. As with the 5-HT2A receptor, none of the tested derivatives
Fig. 2. Overlay of risperidone pose from the risperidone-D2 complex crystal
structure (green) and 3 pose docked to D2 (blue) with D114 residue shown. (For
interpretation of the references to colour in this figure legend, the reader is
referred to the web version of this article.)
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showed affinities at the level of haloperidol, which was the reference
compound (Ki = 2.0 ± 0.2 for haloperidol). In the case of the D2
receptor, we obtained the highest affinities for derivatives 10 and 17,
with 2-methoxy or 2-floromethyl substituents at the phenyl ring on
piperazine (Ki = 132.0 ± 6.7 for 10 and Ki = 102.0 ± 4.8 for 17).
Compound 10 had a three-carbon alkyl linker between the coumarin
and piperazinyl moieties while derivative 17 had a four-carbon linker.
The derivative containing the methoxy group in the C2 position was
one of the most active also after changing the linker from three-carbon
to four-carbon (Ki = 186.0 ± 7.0 for 18). The remaining compounds
showed much lower affinities to D2 receptor.
2.4. Functional assays
Determination of functional activity was carried out for compounds
7 and 16 that showed the highest binding affinity at 5-HT1A receptor in
competition binding studies. As shown in Table 3, both 7 and 16 served
as antagonists at the 5-HT1A receptor. Compound 16 was more potent
than 7 (IC50 = 537 ± 141 vs. 27 ± 2.45, p < 0.01) thus, implying
that the presence of the Br atom at C3 position, together with 3-carbon
linker, rather than the F atom at the same position of the aromatic
determines stronger antagonist activity at the 5-HT1A receptor. How-
ever, compounds 7 and 16 also exhibited moderate potency
(EC50 = 70.5 ± 8.9 and 55.8 ± 7.3, respectively) and low efficacy
(Emax = 118.7 ± 2.1 and 114.5 ± 1.7, respectively) in stimulating
Gi/0 - protein activation in a 5-HT1A – independent manner. This implies
the engagement of an unidentified GPCR in their activity. This result is
associated with receptor heterogeneity of membrane preparations from
rodent tissue that is mostly not observed in transfected cell lines. It is
possible that this additional partial agonist activity at this additional
GPCR could have influenced the pharmacological activity of 7 and 16.
2.5. In vivo experiments
In the TST (tail suspension test) two-way ANOVA revealed sig-
nificant differences between drug-treated and control mice
[(F4,46 = 3.76; p < 0.01) for 7 and (F4,41 = 5.01; p < 0.01) for 16].
Only the reference compound, fluoxetine (20 mg/kg, i.p) decreased
immobility time, whereas compounds 7 and 16 revealed no anti-
depressant activity at any dose studied (1–10 mg/kg, i.p) (Fig. 3A and
Scheme 1. Synthesis of the target compounds 3–10 and 11–18.
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B). The lack of any desirable antidepressant activity could have
stemmed from the lack of functional selectivity for pre- and post-
synaptic sites. It is possible that these compounds exert mutually ex-
clusive biological activities upon binding to both sites. Namely, pre-
synaptic 5-HT1A autoreceptors located at somatodendritic terminals in
the raphe are part of the inhibitory feedback loop and when activated,
decrease serotonin release. Consequently, blockage of the presynaptic
5-HT1A receptors stimulates serotonin discharge and conveys anti-
depressant efficacy by binding to the postsynaptic 5-HT1A receptors
located in various brain regions. This phenomenon was previously de-
scribed in knockout mice, where suppression of 5-HT1A autoreceptor
expression was correlated with decreased depressive-like behavior
[23]. On the other hand, blocking of the postsynaptic sites contributes
to pro-depressive effects. It is also possible that 5-HT1A autoreceptors
show no tonic regulation of serotonin release at baseline and antago-
nists of these receptors only exert their antidepressant action under
serotonin surge e.g following SSRI administration [24]. Moreover, the
binding analysis used did not allow to determine the regional specificity
of 7 and 16 at the presynaptic versus the postsynaptic 5-HT1A receptors,
thus their activity could heavily rely on the dose administered. This
narrow therapeutic index could therefore pose difficulties in dose ti-
tration and possible large drug response variability among future pa-
tients.
3. Conclusions
In summary, we designed and synthesized a novel series of 6-acetyl-
5-hydroxy-4,7-dimethylcoumarin bearing piperazine moieties. New
compounds were designed using molecular docking studies with
homology models of 5-HT1A, 5-HT2A and D2 receptors. Computational
Ki values suggested nanomolar range of the affinity of new derivatives
to 5-HT1A receptors which was consistent with experimental results in
receptor binding assay. Results revealed that six derivatives, both with
electron-withdrawing and electron-donating group, (3, 6, 7, 9, 15, 16
and 18) were able to bind strongly to 5-HT1A receptor and showed
affinities at or below the level of DPAT. The length of the alkyl chain
between the coumarin and piperazinyl moiety had no significant effect
on the affinity of the derivatives for the 5-HT1A receptors.
Computational affinity values for 5-HT2A receptor were analogous to 5-
HT1A receptor and were not completely consistent with the experi-
mental data. In this case, the calculation results were probably influ-
enced by the application of the imperfect 5-HT2AR homology model
based on the β1 adrenergic receptor as well relatively large average
errors connected to the docking protocol. Only compound 16 showed
high affinities to 5-HT2A receptors on the level of mianserin. In the case
of D2 receptors, most of the studies derivatives also showed high
computational affinities, but very low experimental affinities and no
derivative gave results similar to haloperidol. Finally, compounds 7 and
16 were identified as potent antagonists of the 5-HT1A receptors. In the
tail suspension test, however, mice injected with 7 or 16 did not de-
crease or prolong immobility time nor did it affect home cage activity.
4. Experimental section
4.1. Molecular docking studies
In the molecular modelling part we used models of the 5-HT1A and
5-HT2A receptors used in our previous studies with the same sets of
flexible residues and identical parameters [20,21]. D2 model has been
prepared on the basis of the recently-solved structure of this dopamine
receptor [22,25] (PDB code 6cm4). For D2 we have used a
Table 2
Results of binding to serotonergic 5-HT1A and 5-HT2A and dopaminergic D2
receptors of references and test compounds.
Compound 5-HT1AR 5-HT2AR D2R
Ki [nM] ± SEM
3 4.0 ± 0.4 85.0 ± 7.0 148.0 ± 8.8
4 45.0 ± 2.0 216.0 ± 27.0 1647.0 ± 80.2
5 80.0 ± 8.0 > 1000.0 520.0 ± 55.0
6 4.0 ± 0.5 92.0 ± 4.8 190.0 ± 9.6
7 1.0 ± 0.05 17.5 ± 1.6 580.0 ± 15.3
8 106.0 ± 10.5 > 1000.0 NO AFFINITY
9 6.0 ± 0.5 > 1000.0 647.0 ± 38.0
10 – 640.0 ± 30.5 132.0 ± 6.7
11 38.0 ± 5.5 1645.0 ± 172.0 310.0 ± 10.8
12 10.0 ± 1.5 200.0 ± 13.5 343.0 ± 30.3
13 212.0 ± 9.2 > 1000.0 557.0 ± 16.7
14 17.0 ± 2.0 90.0 ± 5.7 1285.0 ± 100.2
15 4.3 ± 0.4 55.0 ± 9.0 406.0 ± 5.4
16 1.0 ± 0.1 8.0 ± 1.1 230.0 ± 5.7
17 67.0 ± 7.0 2500.0 ± 130.0 102.0 ± 4.8
18 3.0 ± 0.3 2500.0 ± 215.0 186.0 ± 7.0
8-OH-DPAT 1.0 ± 0.05 – –
MIANSERIN – 1.7 ± 0.1 –
HALOPERIDOL – – 2.0 ± 0.2
All experiments were performed in duplicates, in three independent experi-
ments. Data were fitted to a one-site curve-fitting equation and Ki values were
estimated from the Cheng − Prusoff equation.
Table 3
Functional activity of 7 and 16 at the serotonergic 5-HT1A receptor in the
[35S]GTPγS assay.
Agonist mode Antagonist mode
Compound EC50 [nM ± SEM] Emax [%±SEM] IC50 [nM ± SEM]
7 70.5 ± 8.9 118.7 ± 2.1 537 ± 141
16 55.8 ± 7.3 114.5 ± 1.7 27 ± 2.45**
8-OH-DPAT 15.3 ± 2.1 148.2 ± 7.3 n.a
Data were expressed as means ± SEM from 3 independent experiments per-
formed in triplicate. In the agonist mode, results were normalized as percentage
of response related to baseline stimulation set to 100%.
(no compound added). In the antagonist mode, results were normalized as the
percentage inhibition of stimulation elicited by an EC80 concentration of 8-OH-
DPAT (62 nM). Emax – maximum possible effect (efficacy); EC50 – half maximal
stimulatory concentration; IC50 – half maximal inhibitory concentration; n.a –
not applicable. Statistical significance was depicted as ** p < 0.01 (7 vs. 16,
equal sum of squares F test). A single assay was performed with each compound
concentrations in triplicate and the whole assay was repeated thrice.
Fig. 3. Antidepressant activity of 7 (A) and 16 (B) (1–10 mg/kg, i.p.) and
fluoxetine (20 mg/kg, i.p) in the tail-suspension test (TST). Asterisks represent
comparisons between the treatment group and control. Two symbols represent
statistical significance of p < 0.001 (one-way ANOVA, Bonferroni’s post-hoc
test, n = 8–10).
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72 × 72× 72 Å box centered on protein binding pocket. All other steps
of docking were performed as in our previous studies [20,21]. Dopa-
mine receptor have been treated as a rigid model with selected residues
(W100, D114, F382, W386, F389, F390, Y416) of the binding pocket
described in a fully flexible manner. Ki values reported in Table 2 were
obtained by converting estimated ligand binding energies using the
standard equation for Gibbs free energy. The expected accuracy of the
docking algorithm is around 1–2 kcal/mol and while the protocol used
in this investigation is generally accurate in predicting ligand poses
within the binding sites of the receptors, it may be often inaccurate
when it comes to estimating binding free energies; it has been shown
that the latter values may err by a few orders of magnitude [27,28].
4.2. Chemistry
General: All syntheses were performed using the microwave oven,
Plazmatronika 1000 W, which was equipped with a single mode niche
suitable and a microwave choked outlet (30% of the power). Melting
points were determined on ElectroThermal 9001 Digital Melting Point
apparatus and are uncorrected. TLC was performed using Kieselgel 60
F254 sheets and spots were visualized by UV – 254 and 365 nm. Silica
gel column chromatography was performer using Kieselgel 60. 1H NMR
and 13C NMR spectra were measured at 25 °C with a Varian Unity plus-
300 spectrometer. Standard Varian software was used (Varian, Inc.,
Palo Alto, CA, USA). High resolution mass spectra were recorded on a
Quattro LCT (TOF). Reagents and solvents were used without further
purification and purchased from Aldrich or Merck.
Compounds 1–2, 3–10 and 11–18 were prepared according to the
previously reported procedures [20,26].
Atom numbering, 1H NMR and 13C NMR spectra of all synthesized
compounds is available in the ESI.
4.2.1. 6-Acetyl-5-(3-(4-(2-chlorophenyl)piperazin-1-yl)propoxy)-4,7-
dimethyl-2H-chromen-2-one (3)
Yield 75%; white solid; m.p. 117–119 °C; Rf = 0.09; 1H NMR
(400 MHz, CDCl3, δ, ppm): 7.36 (1H, d, J= 12 Hz, H-3″), 7.06 (m, 1H,
H-8), 6.99 (1H, d, J = 12.8 Hz, H-6″), 6.94 (2H, m, H-4″, H-5″), 6.18
(1H, s, H-3), 3.91 (2H, t, J = 9 Hz, H-1′), 3.09 (4H, br. s, H-3p, H-5p),
2.62 (6H, m, H-2p, H-6p, H-2′), 2.57 (3H, s, H-12), 2.29 (3H, s, H-10),
2.17 (3H, s, H-9), 1.98 (2H, m, H-3′); 13C NMR (75 MHz, CDCl3, δ,
ppm): 204.6 (C-11), 160.2 (C-2), 154.8 (C-8a), 154.5 (C-4), 152.3 (C-5),
149.4 (C-1″), 139.4 (C-7), 133.7 (C-3″), 130.8 (C-2″), 128.9 (C-5″),
127.8 (C-4″), 123.9 (C-6″), 120.5 (C-6), 116.1 (C-3), 115.3 (C-8), 112.7
(C-4a), 77.4 (C-1′), 54.6 (C-3′), 53.5 (C-3p, C-5p), 51.4 (C-2p, C-6p),
32.7 (C-12), 27.3 (C-2′), 22.7 (C-10), 19.5 (C-9); TOF MS ES+: [M
+NaCl]+ calcd for C26H29O4N2NaCl (491.1714) found 491.1702.
4.2.2. 6-Acetyl-5-(3-(4-(3,5-dimethylphenyl)piperazin-1-yl)propoxy)-4,7-
dimethyl-2H-chromen-2-one (4)
Yield 52%; white solid; m.p. 136–138 °C; Rf = 0.24; 1H NMR
(400 MHz, CDCl3, δ, ppm): 6.97 (s, 1H, H-8), 6.54 (3H, m, H-2″, H-4″,
H-6″), 6.17 (1H, s, H-3), 3.90 (2H, t, J = 8.8 Hz, H-1′), 3.18 (4H, t,
J = 4.8 Hz, H-3p, H-5p), 2.58 (12H, m, H-2p, H-6p, H-9, H-10, H-2′),
2.29 (9H, m, H-12, H-7″, H-8″), 1.95 (2H, m, H-3′); 13C NMR (75 MHz,
CDCl3, δ, ppm): 204.5 (C-11), 160.2 (C-2), 154.8 (C-5), 154.5 (C-4),
152.3 (C-8a), 151.6 (C-1″), 138.8 (C-7), 133.7 (C-3″, C-5″), 121.9 (C-
4″), 116.1 (C-6), 115.3 (C-3), 114.2 (C-2″, C-6″), 112.7 (C-4a, C-8), 76.7
(C-1′), 54.6 (C-3′), 53.4 (C-3p, C-5p), 49.5 (C-2p, C-6p), 32.7 (C-12),
27.3 (C-2′), 22.7 (C-10), 21.8 (C-9), 19.5 (C-7″, C-8″); TOF MS ES+: [M
+H]+ calcd for C28H35O4N2 (463.2597) found 463.2605.
4.2.3. 6-Acetyl-5-(3-(4-(2,5-dimethylphenyl)piperazin-1-yl)propoxy)-4,7-
dimethyl-2H-chromen-2-one (5)
Yield 84%; white solid; m.p. 122–124 °C; Rf = 0.20; 1H NMR
(400 MHz, CDCl3, δ, ppm): 7.06 (1H, d, J = 10 Hz, H-3″), 6.98 (1H, s,
H-8), 6.81 (2H, m, H-4″, H-6″), 6.19 (1H, s, H-3), 3.91 (2H, t,
J= 8.8 Hz, H-1′), 2.94 (4H, t, J= 6.2 Hz, H-3p, H-5p), 2.63 (9H, m, H-
2p, H-6p, H-12, H-2′), 2.57 (3H, s, H-10), 2.30 (6H, s, H-7″, H-8″), 2.26
(3H, s, H-9), 1.99 (2H, m, H-3′); 13C NMR (75 MHz, CDCl3, δ, ppm):
204.5 (C-11), 160.2 (C-2), 154.8 (C-5), 154.5 (C-4), 152.3 (C-8a), 151.4
(C-1″), 139.4 (C-7), 136.3 (C-5″), 133.7 (H-3″), 131.1 (C-2″), 129.4 (C-
4″), 123.9 (C-6), 119.9 (C-6″), 116.1 (C-3), 112.7 (C-4a), 76.8 (C-1′),
54.7 (C-3′), 53.9 (C-3p, C-5p), 51.8 (C-2p, C-6p), 32.7 (C-12), 27.4 (C-
2′), 22.7 (C-10), 21.4 (C-9), 19.5 (C-7″), 17.6 (C-8″); TOF MS ES+: [M
+H]+ calcd for C28H35O4N2 (463.2597) found 463.2609.
4.2.4. 6-Acetyl-5-(3-(4-(2-bromophenyl)piperazin-1-yl)propoxy)-4,7-
dimethyl-2H-chromen-2-one (6)
Yield 78%; brown solid; m.p. 124–125 °C; Rf = 0.20; 1H NMR
(400 MHz, CDCl3, δ, ppm): 7.55 (1H, d, J= 12.4 Hz, H-3″), 7.27 (1H, t,
J= 11.2 Hz, H-5″), 7.06 (1H, d, J= 12.8 Hz, H-6″), 6.91 (2H, m, H-8,
H-4″), 6.18 (1H, s, H-3), 3.91 (2H, t, J= 9 Hz, H-1′), 3.07 (4H, br. s., H-
3p, H-5p), 2.64 (9H, m, H-2p, H-6p, H-12, H-3′), 2.29 (3H, s, H-10),
2.17 (3H, s, H-9), 1.99 (2H, m, H-2′); 13C NMR (75 MHz, CDCl3, δ,
ppm): 204.5 (C-11), 160.1 (C-2), 154.8 (C-5), 154.4 (C-4), 152.3 (C-8a),
150.7 (C-1″), 139.4 (C-7), 133.9 (C-3″), 133.6 (H-4″), 128.4 (C-6″, C-
5″), 124.5 (C-2″), 121.1 (C-6), 120.0 (C-3), 116.06 (C-8), 112.7 (C-4a),
76.7 (C-1′), 54.6 (C-3′), 53.5 (C-3p, C-5p), 51.8 (C-2p, C-6p), 32.6 (C-
12), 27.3 (C-2′), 22.7 (C-10), 19.5 (C-9); TOF MS ES+: [M+NaBr]+
calcd for C26H29O4N2NaBr (535.1208) found 535.1227.
4.2.5. 6-Acetyl-5-(3-(4-(3-bromophenyl)piperazin-1-yl)propoxy)-4,7-
dimethyl-2H-chromen-2-one (7)
Yield 73%; yellow solid; m.p. 126–127 °C; Rf = 0.08; 1H NMR
(400 MHz, CDCl3, δ, ppm): 6.97 (5H, m, H-2″, H-4″, H-5″, H-6″, H-8″),
6.17 (1H, s, H-3), 3.92 (2H, t, J= 8.8 Hz, H-1′), 3.20 (4H, t, J= 6.6 Hz,
H-3p, H-5p), 2.59 (9H, m, H-2p, H-6p, H-12, H-2′), 2.58 (3H, s, H-10),
2.29 (3H, s, H-9), 1.95 (2H, m, H-3′); 13C NMR (75 MHz, CDCl3, δ,
ppm): 204.5 (C-11), 160.1 (C-2), 154.8 (C-5), 154.3 (C-4), 152.6 (C-8a),
152.2 (C-1″), 139.3 (C-7), 133.6 (C-5″), 130.4 (C-3″), 123.4 (H-4″),
122.3 (C-6), 118.8 (C-2″), 116.1 (C-6″), 115.3 (C-3), 114.5 (C-8), 112.7
(C-4a), 76.6 (C-1′), 54.2 (C-3′), 53.1 (C-3p, C-5p), 48.8 (C-2p, C-6p),
32.7 (C-12), 27.2 (C-2′), 22.7 (C-10), 19.5 (C-9); TOF MS ES+: [M
+NaBr]+ calcd for C26H29O4N2NaBr (535.1208) found 535.1221.
4.2.6. 6-Acetyl-5-(3-(4-(3-fluorophenyl)piperazin-1-yl)propoxy)-4,7-
dimethyl-2H-chromen-2-one (8)
Yield 81%; brown solid; m.p. 104–106 °C;; Rf = 0.22; 1H NMR
(400 MHz, CDCl3, δ, ppm): 7.20 (2H, m, H-5″, H-8), 6.98 (1H, s, H-2″),
6.57 (2H, m, H-4″, H-6″), 6.18 (1H, s, H-3), 3.90 (2H, t, J = 10 Hz, H-
1′), 3.23 (4H, br. s, H-3p, H-5p), 2.61 (12H, m, H-2p, H-6p, H-12, H-10,
H-3′), 2.29 (3H, s, H-9), 1.99 (2H, m, H-2′); 13C NMR (75 MHz, CDCl3,
δ, ppm): 204.5 (C-11), 165.6 (C-3″), 162.4 (C-2), 160.1 (C-6), 154.8 (C-
4), 152.1 (C-8a), 139.3 (C-1″), 133.7 (C-7), 130.4 (C-5″), 116.1 (C-6),
115.4(H-3), 112.7 (C-8), 111.4 (C-4″), 106.4 (C-6″), 103.1 (C-4a), 102.8
(C-2″), 76.4 (C-1′), 54.5 (C-3′), 53.0 (C-3p, C-5p), 48.6 (C-2p, C-6p),
32.7 (C-12), 27.1 (C-2′), 22.6 (C-10), 19.5 (C-9); TOF MS ES+: [M
+Na]+ calcd for C26H29O4N2 FNa (475.2009) found 475.1998.
4.2.7. 6-Acetyl-4,7-dimethyl-5-(3-(4-(2-(trifluoromethyl)phenyl)
piperazin-1-yl)propoxy)-2H-chromen-2-one (9)
Yield 74%; white solid; m.p. 117–118 °C; Rf = 0.26; 1H NMR
(400 MHz, CDCl3, δ, ppm): 7.62 (1H, d, J= 10.4 Hz, H-3″), 7.51 (1H, t,
J = 10.4 Hz, H-5″), 7.38 (1H, d, J = 10.4 Hz, H-6″), 7.22 (1H, m, H-
4″), 6.98 (1H, s, H-8), 6.18 (1H, s, H-3), 3.91 (2H, t, J= 8.8 Hz, H-1′),
2.96 (4H, t, J = 6.2 Hz, H-3p, H-5p), 2.56 (12H, m, H-2p, H-6p, H-12,
H-2′, H-10), 2.30 (3H, s, H-9), 1.98 (2H, m, H-3′); 13C NMR (75 MHz,
CDCl3, δ, ppm): 204.5 (C-11), 160.2 (C-2), 154.8 (C-5), 154.5 (C-4),
152.7 (C-8a), 152.3 (C-1″), 139.4 (C-7), 133.7 (C-5″), 132.9 (C-3″),
127.4 (H-7″), 127.3 (C-4″), 127.3 (C-6), 124.9 (C-2″), 116.1 (C-6″),
115.3 (C-8), 112.7 (C-4a), 76.8 (C-1′), 54.7 (C-3′), 53.7 (C-3p, C-5p),
53.6 (C-2p, C-6p), 32.7 (C-12), 27.3 (C-2′), 22.7 (C-10), 19.5 (C-9); TOF
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MS ES+: [M+H]+ calcd for C27H30O4N2F3 (503.2161) found
503.2158.
4.2.8. 6-Acetyl-5-(3-(4-(2-methoxyphenyl)piperazin-1-yl)propoxy)-4,7-
dimethyl-2H-chromen-2-one (10).
Yield 75%; white solid; m.p. 122–124 °C; Rf = 0.33; 1H NMR
(400 MHz, CDCl3, δ, ppm): 6.93 (5H, m, H-8, H-3″, H-4″, H-5″, H-6″),
6.17 (1H, s, H-3), 3.90 (5H, m, H-1′, H-7″), 3.10 (4H, br. s., H-3p, H-
5p), 2.62 (4H, m, H-2p, H-6p), 2.55 (3H, s, H-12), 2.53 (3H, s, H-10),
2.51 (2H, m, H-2′), 2.29 (3H, s, H-9), 1.98 (2H, m, H-3′); 13C NMR
(75 MHz, CDCl3, δ, ppm): 204.5 (C-11), 160.2 (C-2), 154.8 (C-1′),
154.5 (C-5), 152.4 (C-4), 152.3 (C-8a), 141.4 (C-7), 139.4 (C-2″), 133.6
(C-6″), 123.1 (H-4″), 121.2 (C-5″), 118.4 (C-6), 116.1 (C-3″), 115.3 (C-
3), 112.7 (C-8), 111.4 (C-4a), 76.8 (C-1′), 54.5 (C-3′), 54.7 (C-3p, C-5p),
53.6 (C-7″), 50.8 (C-2p, C-6p), 32.7 (C-12), 27.4 (C-2′), 22.7 (C-10),
19.5 (C-9); TOF MS ES+: [M+H]+ calcd for C27H33O5N2 (465.2389)
found 465.2380.
4.2.9. 6-Acetyl-5-(4-(4-(2-chlorophenyl)piperazin-1-yl)butoxy)-4,7-
dimethyl-2H-chromen-2-one (11)
Yield 54%; brown solid; m.p. 97–99 °C; Rf = 0.15; 1H NMR
(400 MHz, CDCl3, δ, ppm): 7.35 (1H, d, J= 12 Hz, H-3″), 7.23 (1H, d,
J= 8 Hz, H-6″), 7.05 (3H, H-8, H-4″, H-5″), 6.19 (1H, s, H-3), 3.85 (2H,
t, J = 8 Hz, H-1′), 3.17 (4H, br.s, H-3p, H-5p), 2.61 (12H, m, H-2p, H-
6p, H-4′, H-10, H-12), 2.30 (3H, s, H-9), 1.71 (4H, m, H-2′, H-3′); 13C
NMR (75 MHz, CDCl3, δ, ppm): 205.1 (C-11), 160.0 (C-2), 154.8 (C-6),
153.4 (C-4), 151.7 (C-8a), 147.1 (C-1″), 138.9 (C-7), 133.8 (C-3″),
130.9 (C-2″), 128.9 (C-5″), 128.2 (C-4″), 125.6 (C-6″), 121.3 (C-6),
116.4 (C-3), 115.6 (C-8), 112.7 (C-4a), 77.6 (C-1′), 57.3 (C-3′), 52.6 (C-
3p, C-5p), 48.1 (C-2p, C-6p), 33.2 (C-12), 29.2 (C-2′), 27.2 (C-3′), 22.5
(C-10), 19.3 (C-9); TOF MS ES+: [M+H]+ calcd for
C27H32ClO4N2 (482.9931) found 483.2005.
4.2.10. 6-Acetyl-5-(4-(4-(3,5-dimethylphenyl)piperazin-1-yl)butoxy)-4,7-
dimethyl-2H-chromen-2-one (12)
Yield 54%; oil; Rf = 0.10; 1H NMR (400 MHz, CDCl3, δ, ppm): 6.99
(1H, s, H-8) 6.76 (2H, s, H-2″, H-6″), 6.54 (1H, s, H-4″), 6.19 (1H, s, H-
3), 3.85 (2H, t, J= 9 Hz, H-1′), 3.20 (4H, m, H-3p, H-5p), 2.59 (9H, m,
H-9, H-10, H-12), 2.46 (4H, m, H-2p, H-6p), 2.31 (2H, m, H-4′), 2.29
(6H, s, H-7″, H-8″), 2.18 (2H, m, H-2′), 1.81 (2H, m, H-3′); 13C NMR
(75 MHz, CDCl3, δ, ppm): 204.6 (C-11), 160.2 (C-2), 154.9 (C-5), 154.3
(C-4), 151.6 (C-8a), 143.2 (C-1″), 139.4 (C-7), 133.6 (C-5″, C-3″), 124.2
(C-4″), 116.1 (H-2″, C-C6″), 113.6 (C-3), 110.3 (C-8), 108.0(C-4a), 78.4
(C-1′), 58.3 (C-4′), 53.5 (C-3p, C-5p), 49.5 (C-2p, C-6p), 32.7 (C-12),
27.4 (C-2′), 24.3 (C-3′), 23.8 (C-3″), 23.3 (C-10), 22.2 (C-9), 21.5 (C7″,
C-8″); TOF MS ES+: [M+Na]+ calcd for C29H36O4N2Na (499.2573)
found 499.2584.
4.2.11. 6-Acetyl-5-(4-(4-(2,5-dimethylphenyl)piperazin-1-yl)butoxy)-4,7-
dimethyl-2H-chromen-2-one (13)
Yield 56%; brown solid; m.p. 113–115 °C; Rf = 0.20; 1H NMR
(400 MHz, CDCl3, δ, ppm): 7.06 (1H, d, J= 10 Hz, H-3″) 6.98 (1H, s, H-
8), 6.81 (2H, m, H-4″, H-6″), 6.18 (1H, s, H-3), 3.84 (2H, t, J= 9 Hz, H-
1′), 2.93 (4H, t, J= 6 Hz, H-3p, H-5p), 2.58 (6H, m, H-2p, H-6p, H-4′),
2.56 (3H, s, H-10), 2.30 (6H, m, H-9, H-12), 2.25 (3H, s, H-8″), 2.17
(3H, s, H-7″), 1.83 (2H, m, H-2′), 1.61 (2H, m, H-3′); 13C NMR (75 MHz,
CDCl3, δ, ppm): not registered; TOF MS ES+: [M+Na]+ calcd for
C29H36O4N2Na (499.2573) found 499.2584.
4.2.12. 6-Acetyl-5-(4-(4-(2-bromophenyl)piperazin-1-yl)butoxy)-4,7-
dimethyl-2H-chromen-2-one (14)
Yield 61%; oil; Rf = 0.35; 1H NMR (400 MHz, CDCl3, δ, ppm): 7.02
(4H, m, H-3″, H-4″, H-5″, H-8), 6.82 (1H, d, J = 13.2 Hz, H-6″), 6.17
(1H, s, H-3), 3.83 (2H, t, J= 9 Hz, H-1′), 3.19 (4H, t, J= 6.6 Hz, H-3p,
H-5p), 2.57 (7H, m, H-2p, H-6p, H-12), 2.24 (2H, m, H-4′), 2.28 (3H, s,
H-10), 2.16 (3H, s, H-9), 1.81 (2H, m, H-2′), 1.65 (2H, m, H-3′); 13C
NMR (75 MHz, CDCl3, δ, ppm): 204.6 (C-11), 160.1 (C-2), 158.9 (C-5),
157.9 (C-4), 154.4 (C-8a), 152.3(C-1″), 139.4 (C-7), 133.6 (C-3″), 130.5
(C-4″), 124.9 (C-5″), 123.4 (C-6″), 122.3 (C-2″), 118.7 (C-6), 116.1 (C-
3), 115.4 (C-8), 114.4 (C-4a), 78.4 (C-1′), 62.6 (C-4′), 58.0 (C-3p), 53.2
(C-5p), 48.8 (C-2p), 44.8 (C-6p), 32.8 (C-12), 27.9 (C-2′), 23.3 (C-3′),
21.3 (C-10), 19.5 (C-9); TOF MS ES+: [M+H]+ calcd for
C27H32O4N2Br (527.1545) found 527.1554.
4.2.13. 6-Acetyl-5-(4-(4-(3-bromophenyl)piperazin-1-yl)butoxy)-4,7-
dimethyl-2H-chromen-2-one (15)
Yield 62%; oil; Rf = 0.29; 1H NMR (400 MHz, CDCl3, δ, ppm): 7.03
(5H, m, H-2″, H-4″, H-5″, H-6″, H-8), 6.17 (1H, s, H-3), 3.83 (2H, t,
J = 9 Hz, H-1′), 3.20 (4H, t, J = 6.6 Hz, H-3p, H-5p), 2.58 (7H, m, H-
2p, H-6p, H-12), 2.24 (2H, m, H-4′), 2.29 (3H, s, H-10), 2.17 (3H, s, H-
9), 1.82 (2H, m, H-2′), 1.63 (2H, m, H-3′); 13C NMR (75 MHz, CDCl3, δ,
ppm): 204.4 (C-11), 157.9 (C-2), 157.4 (C-5), 154.4 (C-4), 150.2 (C-8a,
C-1″), 143.2 (C-7), 131.0 (C-5″), 124.8 (C-3″), 123.5 (C-4″), 122.4 (C-
5), 119.6 (C-2″), 118.8 (C-6″), 115.4 (C-3), 113.6 (C-8), 110.3 (C-4a),
69.0 (C-1′), 62.6 (C-5p), 59.4 (C-3p), 53.2 (C-4′), 48.8 (C-6p), 44.8 (C-
2p), 32.5 (C-12), 27.4 (C-2′), 24.3 (C-3′), 23.8 (C-10), 21.6 (C-9); TOF
MS ES+: [M+Na]+ calcd for C27H31O4N2NaBr (549.1365) found
549.1371.
4.2.14. 6-Acetyl-5-(4-(4-(3-fluorophenyl)piperazin-1-yl)butoxy)-4,7-
dimethyl-2H-chromen-2-one (16)
Yield 67%; oil; Rf = 0.23; 1H NMR (400 MHz, CDCl3, δ, ppm): 7.20
(1H, m, H-5″), 6.97 (1H, s, H-8), 6.61 (3H, m, H-2″, H-4″, H-6″), 6.18
(1H, s, H-3), 3.84 (2H, t, J = 8 Hz, H-1′), 3.21 (4H, t, J = 8 Hz, H-3p,
H-5p), 2.60 (7H, m, H-2p, H-6p, H-12), 2.55 (3H, s, H-10), 2.43 (2H, m,
H-4′), 2.29 (3H, s, H-9), 1.83 (2H, m, H-2′), 1.64 (2H, m, H-3′); 13C
NMR (75 MHz, CDCl3, δ, ppm): 204.6 (C-11), 165.6 (C-3″), 162.4 (C-2),
160.2 (C-5), 154.8 (C-4), 153.1 (C-8a), 139.4 (C-1″), 133.6 (C-7), 130.3
(C-5″), 116.1 (C-6), 112.7 (C-3), 11.2 (C-8), 108.5 (C-4″), 105.8 (C-6″),
104.1 (C-4a), 102.6 (C-2″), 78.4 (C-1′), 62.6 (C-4′), 58.0 (C-5p), 53.2
(C-3p), 48.8 (C-6p), 44.8 (C-2p), 32.7 (C-12), 27.9 (C-2′), 22.7 (C-3′),
21.6 (C-10), 19.5 (C-9); TOF MS ES+: [M+H]+ calcd for C27H32O4N2F
(467.2346) found 467.2335.
4.2.15. 6-Acetyl-4,7-dimethyl-5-(4-(4-(2-(trifluoromethyl)phenyl)
piperazin-1-yl)butoxy)-2H-chromen-2-one (17)
Yield 68%; oil; Rf = 0.25; 1H NMR (400 MHz, CDCl3, δ, ppm): 7.62
(1H, d, J= 10.4 Hz, H-3″), 7.51 (1H, t, J= 10.2 Hz, H-5″), 7.37 (1H, d,
J = 10.4 Hz, H-6″), 7.22 (1H, m, H-4″), 6.97 (1H, s, H-8), 6.18 (1H, s,
H-3), 4.07 (2H, t, J = 8.4 Hz, H-1′), 3.84 (2H, t, J = 9 Hz, H-4′),
2.97 (4H, m, H-3p, H-5p), 2.60 (7H, m, H-2p, H-6p, H-12), 2.29 (3H, s,
H-10), 2.17 (3H, s, H-9), 1.79 (4H, m, H-2′, H-3′); 13C NMR (75 MHz,
CDCl3, δ, ppm): 204.6 (C-11), 161.2 (C-2), 157.5 (C-5), 154.3 (C-4),
152.4 (C-8a), 149.0 (C-1″), 143.2 (C-7), 132.9 (C-5″), 127.4 (C-3″),
124.9 (C-7″), 124.1 (C-4″), 116.1 (C-6), 115.3 (C-2″), 113.6 (C-3),
110.3 (C-8), 108.4 (C-6″), 108.0 (C-4a), 78.5 (C-1′), 69.0 (C-4′), 58.3
(C-3p, 5p), 53.8 (C-2p, 6p), 27.5 (C-12), 24.7 (C-2′), 24.3 (C-3′), 23.9
(C-10), 22.2 (C-9); TOF MS ES+: [M+H]+ calcd for C28H32O4
N2F3 (517.2314) found 517.2302.
4.2.16. 6-Acetyl-5-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butoxy)-4,7-
dimethyl-2H-chromen-2-one (18)
Yield 71%; oil; Rf = 0.23; 1H NMR (400 MHz, CDCl3, δ, ppm): 6.94
(4H, m, H-3″, H-4″, H-5″, H-6″), 6.66 (1H, s, H-8), 6.04 (1H, s, H-3),
3.84 (2H, t, J= 10 Hz, H-1′), 3.11 (3H, br. s, H-7″), 2.65 (8H, m, H-2p,
H-3p, H-5p, H-6p), 2.55 (6H, s, H-10, H-12), 2.45 (2H, m, H-4′), 2.29
(3H, s, H-9), 1.82 (2H, m, H-2′), 1.67 (2H, m, H-3′); 13C NMR (75 MHz,
CDCl3, δ, ppm): 204.6 (C-11), 166.4 (C-2), 160.5 (C-1″), 158.2 (C-5),
155.8 (C-4), 152.4 (C-8a), 143.5 (C-7), 141.5 (C-2″), 125.2 (C-6″),
121.2 (C-4″), 118.3 (C-6), 116.1 (C-3″), 112.9 (C-8), 109.4 (C-4a), 78.4
(C-1′), 60.3 (C-7″), 58.2 (C-3p), 55.7 (C-5p), 53.6 (C-4′), 50.8 (C-2p),
46.0 (C-6p), 32.7 (C-12), 24.4 (C-2′), 22.8 (C-3′), 21.5 (C-10), 19.5 (C-
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9); TOF MS ES+: [M+H]+ calcd for C28H35O5N2 (479.2546) found
479.2534.
4.3. In vitro affinity tests
4.3.1. Preparation of solutions of test and reference compounds
10 mM stock solutions of tested compounds were prepared in
DMSO. Serial dilutions of compounds were prepared in 96-well mi-
croplate in assay buffers using automated pipetting system epMotion
5070 (Eppendorf). Each compound was tested in 8 concentrations from
10–5 to 10–12 M (final concentration).
4.3.2. 5-HT1A receptor binding assay
Radioligand binding was performed using membranes from CHO-K1
cells stably transfected with the human 5-HT1A receptor (PerkinElmer).
All assays were carried out in duplicates. 50 µl working solution of the
tested compounds, 50 µl [3H]-8-OH-DPAT (final concentration 0.4 nM)
and 150 µl diluted membranes (10 µg protein per well) prepared in
assay buffer (50 mM Tris, pH 7.4, 4 mM CaCl2, 0.1% ascorbic acid)
were transferred to polypropylene 96-well microplate using 96-wells
pipetting station Rainin Liquidator (MettlerToledo). Serotonin (10 μM)
was used to define nonspecific binding. Microplate was covered with a
sealing tape, mixed and incubated for 60 min at 27 °C. The reaction was
terminated by rapid filtration through GF/B filter mate presoaked with
0.5% polyethyleneimine for 30 min. Ten rapid washes with 200 µl
50 mM Tris buffer (4 °C, pH 7.4) were performed using automated
harvester system Harvester-96 MACH III FM (Tomtec). The filter mates
were dried at 37 °C in forced air fan incubator and then solid scintillator
MeltiLex was melted on filter mates at 90 °C for 5 min. Radioactivity
was counted in MicroBeta2 scintillation counter (PerkinElmer). Raw
data (cpm) representing radioligand binding was plotted as a function
of the logarithm of the final molar concentration of the test and re-
ference compound. Non-linear regression of the normalized (percent
radioligand binding compared to that observed in the absence of test or
reference compound - total binding) raw data was performed in
GraphPad Prism 6.0 (GraphPad Software) using the built-in three
parameter logistic model describing ligand competition binding to
radioligand-labeled sites. The log IC50 estimated from the data is used
to obtain the Ki by applying the Cheng-Prusoff approximation.
Goodness of fit was evaluated on the R2 value and absolute sum of
squares. Quality of the assays was evaluated by checking Ki value for
control compounds with value obtained from validation experiments.
4.3.3. 5-HT2A receptor binding assay
Radioligand binding was performed using membranes from CHO-K1
cells stably transfected with the human 5-HT2A receptor (PerkinElmer)
according to the manufacturer’s instructions. All assays were carried
out in duplicates. 50 µl working solution of the tested compounds, 50 µl
[3H]-ketanserin (final concentration 1 nM) and 150 µl diluted mem-
branes (5 µg protein per well) prepared in assay buffer (50 mM Tris, pH
7.4, 4 mM CaCl2, 0.1% ascorbic acid) were transferred to polypropylene
96-well microplate using 96-wells pipetting station Rainin Liquidator
(MettlerToledo). Mianserin (10 μM) was used to define nonspecific
binding. Microplate was covered with a sealing tape, mixed and in-
cubated for 60 min at 27 °C. The reaction was terminated by rapid
filtration through GF/B filter mate presoaked with 0.5% poly-
ethyleneimine for 30 min. Ten rapid washes with 200 µl 50 mM Tris
buffer (4 °C, pH 7.4) were performed using automated harvester system
Harvester-96 MACH III FM (Tomtec). The filter mates were dried at
37 °C in forced air fan incubator and then solid scintillator MeltiLex was
melted on filter mates at 90 °C for 5 min. Radioactivity was counted in
MicroBeta2 scintillation counter (PerkinElmer). Data were fitted to a
one-site curve-fitting equation with Prism 6 (GraphPad Software) and
Ki values were estimated from the Cheng − Prusoff equation.
4.3.4. D2 receptor binding assay
Radioligand binding was performed using membranes from CHO-K1
cells stably transfected with the human D2 receptor (PerkinElmer). All
assays were carried out in duplicates. 50 µl working solution of the
tested compounds, 50 µl [3H]-methylspiperone (final concentration
0.4 nM) and 150 µl diluted membranes (3 µg protein per well) prepared
in assay buffer (50 mM Tris, pH 7.4, 50 mM HEPES, 50 mM NaCl, 5 mM
MgCl2, 0.5 mM EDTA) were transferred to polypropylene 96-well mi-
croplate using 96-wells pipetting station Rainin Liquidator
(MettlerToledo). Haloperidol (10 μM) was used to define nonspecific
binding. Microplate was covered with a sealing tape, mixed and in-
cubated for 60 min at 37 °C. The reaction was terminated by rapid
filtration through GF/B filter mate presoaked with 0.5% poly-
ethyleneimine for 30 min. Ten rapid washes with 200 µl 50 mM Tris
buffer (4 °C, pH 7.4) were performed using automated harvester system
Harvester-96 MACH III FM (Tomtec). The filter mats were dried at 37 °C
in forced air fan incubator and then solid scintillator MeltiLex was
melted on filter mates at 90 °C for 5 min. Radioactivity was counted in
MicroBeta2 scintillation counter (PerkinElmer). Data were fitted to a
one-site curve-fitting equation with Prism 6 (GraphPad Software) and
Ki values were estimated from the Cheng − Prusoff equation.
4.3.5. Functional [35S]GTPγS assay
The assay was performed on homogenates from rat hippocampi
(20 μg/ml) according to the method described previously with some
modifications [29]. In the agonist mode, increasing concentrations
(10−10–10−5 M) of 7 and 16 were incubated with 0.8 nM [35S]GTPγS
for 5 min. At 30 °C in 50 mM Tris-HCl, pH = 7.4 binding buffer sup-
plemented with 1 mM EGTA, 3 mM MgCl2, 100 mM NaCl and 30 µM
GDP in a total volume of 250 µl. Unlabeled GTPγS was used to de-
termine non-specific binding. In the antagonist mode, 62 nM of 8-OH-
DPAT was added to wells containing each triplicate concentration of 7
and 16. Samples were then vacuum mounted onto 96-well Unifilter®
Plates (Perkin Elmer, USA) and filtered with 2 ml of wash buffer
(50 mM Tris-HCl, pH = 7.4) using the FilterMate Harvester (Perkin
Elmer, USA). After overnight drying at RT, 45 µl of EcoScint-20 scin-
tillant (Perkin Elmer, USA) was added to every filter well. Filter-bound
radioactivity was counted in a Trilux MicroBeta2 counter (Perkin Elmer,
USA). Data were fitted with non-linear regression and with the
GraphPad Prism 5.0 software. The Cheng-Prusoff equation was used to
determine efficacy (Emax), potency (EC50) and half-maximal inhibitory
activity (IC50). Baseline activation was set to 100%.
4.3.5.1. In vivo experiments. Subjects were male, 8–12-week old BALB/
c mice. Animals were housed in a room provided by the animal facility
at the Institute of Genetics and Animal Breeding, Polish Academy of
Sciences. Mice were kept in groups of up to 4 individuals in
conventional clear cages with sawdust bedding and environmental
enrichment. A 12/12 h light cycle, ambient temperature of 22 ± 2 °C
and 55 ± 10% humidity were ensured. Animals had ad libitum access
to pelleted food (Labofeed H, Kcynia, Poland) and tap water. In vivo
experiments were given ethical clearance from the II Local Ethics
Committee for Animal Experimentation in Warsaw (decision no.
WAW2/159/2018).
Antidepressant activity was assessed in the tail suspension test [30].
Compounds (1–10 mg/kg) were dissolved in 5% Kalliphor and 15%
DMSO in saline and delivered intraperitoneally (i.p) at Control mice
received vehicle. Fluoxetine (20 mg/kg, i.p) served as positive control.
Thirty minutes after injection, mice were suspended by the tail on a
hook with adhesive tape in a wooden box painted light gray (h:
680 × w: 365 × d: 280 mm). The time the animal spent actively
struggling was scored for 6 min. with the help of the EthoVision be-
havioural tracking system (Noldus Information Technology, The Neth-
erlands). Drug solutions were prepared and coded by a technician that
did not take part in behavioral testing. Animals were assigned to
treatment conditions based on allocation of random numbers generated
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by Excel. Care was also taken that animals in the same treatment group
were of similar weight (± 2 g).
Statistical analysis Data were analyzed with GraphPad Prism 5.04
software for Windows (GraphPad Software, San Diego California USA,
www.graphpad.com). Results were expressed as mean ± SEM from 3
independent experiments. Efficacy (Emax) and potency (EC50) were
calculated from the Cheng - Prusoff equation and expressed as
means ± SEM from two separate experiments. Differences in potency
and efficacy were calculated with the extra sum of squares F test. Raw
data from the in vivo experiments were analysed with one-way ANOVA
followed by the Dunnett's Multiple Comparison Test. Results were
considered significant at p < 0.05.
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